Literature DB >> 7878032

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.

G Douce1, C Turcotte, I Cropley, M Roberts, M Pizza, M Domenghini, R Rappuoli, G Dougan.   

Abstract

A nontoxic mutant (LTK7) of the Escherichia coli heat-labile enterotoxin (LT) lacking ADP-ribosylating activity but retaining holotoxin formation was constructed. By using site-directed mutagenesis, the arginine at position 7 of the A subunit was replaced with lysine. This molecule, which was nontoxic in several assays, was able to bind to eukaryotic cells and acted as a mucosal adjuvant for co-administered proteins; BALB/c mice immunized intranasally with LTK7 and ovalbumin developed high levels of serum and local antibodies to ovalbumin and toxin. In addition, mice immunized intranasally with fragment C of tetanus toxin and LTK7 were protected against lethal challenge with tetanus toxin. Thus nontoxic mutants of heat-labile toxin can act as effective intranasal mucosal adjuvants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7878032      PMCID: PMC42576          DOI: 10.1073/pnas.92.5.1644

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Detection of heat-labile Escherichia coli enterotoxin with the use of adrenal cells in tissue culture.

Authors:  S T Donta; H W Moon; S C Whipp
Journal:  Science       Date:  1974-01-25       Impact factor: 47.728

2.  Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant.

Authors:  R J Jackson; K Fujihashi; J Xu-Amano; H Kiyono; C O Elson; J R McGhee
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

Review 3.  1993 Colworth Prize Lecture. The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development.

Authors:  G Dougan
Journal:  Microbiology       Date:  1994-02       Impact factor: 2.777

Review 4.  Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems.

Authors:  J Holmgren; N Lycke; C Czerkinsky
Journal:  Vaccine       Date:  1993-09       Impact factor: 3.641

5.  Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli.

Authors:  N F Fairweather; V A Lyness; D J Maskell
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

Review 6.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.

Authors:  B D Spangler
Journal:  Microbiol Rev       Date:  1992-12

7.  Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.

Authors:  J D Clements; N M Hartzog; F L Lyon
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

Review 8.  Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes.

Authors:  T O Nashar; T Amin; A Marcello; T R Hirst
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

9.  Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen.

Authors:  A D Wilson; A Robinson; L Irons; C R Stokes
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

10.  The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity.

Authors:  N Lycke; T Tsuji; J Holmgren
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

View more
  82 in total

1.  Vaccines against gut pathogens.

Authors:  P Mastroeni; F Bowe; R Cahill; C Simmons; G Dougan
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

Review 2.  Interleukin 12 and innate molecules for enhanced mucosal immunity.

Authors:  P N Boyaka; J W Lillard; J McGhee
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

3.  Mutational analysis of the Helicobacter pylori vacuolating toxin amino terminus: identification of amino acids essential for cellular vacuolation.

Authors:  D Ye; S R Blanke
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 4.  The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.

Authors:  G Dougan; M Ghaem-Maghami; D Pickard; G Frankel; G Douce; S Clare; S Dunstan; C Simmons
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

5.  Bacterial spores as vaccine vehicles.

Authors:  Le H Duc; Huynh A Hong; Neil Fairweather; Ezio Ricca; Simon M Cutting
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  Mucosal immunogenicity of plant lectins in mice.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; D T O'Hagan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 7.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 8.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  The identification of plant lectins with mucosal adjuvant activity.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; D T O'Hagan
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

10.  Vaccines timeline. Interview by Philip Cohen.

Authors:  M A Liu
Journal:  BMJ       Date:  1999-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.